UK Company Championing Near-Patient Testing for Therapeutic Differentiation
Abingdon Health is championing the use of cost-effective near-patient testing to aid the therapeutic market share and profitability ambitions of pharmaceutical companies in an industry that is set for increased competition.
By: Abingdon Health
The use of near-patient test and mHealth rapid diagnostic technology is a solution for aiding therapeutic differentiation:
As an experienced contract manufacturing organisation (CMO), Abingdon Health is helping global pharmaceutical partners cement their therapeutic market ambitions through the use of near-patient lateral flow immunoassays.
These technologies offer a variety of testing and monitoring solutions owing to their flexibility in being able to offer qualitative, semi-quantitative or quantitative results and detect different markers in a variety of sample types.
Greater Therapeutic Up-Take Owing To Intuitive Drug Marker Monitoring
A big concern for clinicians and patients alike is slow results delivery and any subsequent delay in drug therapy guidance owing to labour intensive laboratory monitoring methods.
The competitive advantage and growth opportunities for the pharmaceutical industry lie in greater uptake in a therapeutic, or a biosimilar for that matter, owing to the quick and intuitive way in which a drug can be monitored.
Policymakers are more likely to choose the use of approved drugs if the monitoring methods aids the concerns of busy and financially-
See How We Can Aid Your Therapeutic Differentiation Strategy
Learn how Abingdon Health's value for money services could deliver a quality, complementary near-patient test to aid your therapeutic differentiation strategy. Download our brochure at https://www.abingdonhealth.com/